Skip to main content
NewslettersWatchlist

Poseida Therapeutics Inc(PSTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.12
Day High3.38
Open:3.34
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
AllPennyStocks.com
Biotech Soars on Research Collaboration And License Agreement Release
PR Newswire
Poseida Therapeutics Announces Leadership Transition
PR Newswire
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023
PR Newswire
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update
PR Newswire
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
PR Newswire
Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders
PR Newswire
Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day
PR Newswire
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis
PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
PR Newswire
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
PR Newswire
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
PR Newswire
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations
PR Newswire
Poseida Therapeutics Announces Board Change
PR Newswire
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
PR Newswire
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
PR Newswire
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
PR Newswire
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting
PR Newswire
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022
PR Newswire
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Spotlight Growth
Poseida Therapeutics (NASDAQ: PSTX) Enters into Strategic Collaboration Agreement with Roche to Develop Next-Gen Allogeneic CAR-T Cell Therapies
PR Newswire
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
PR Newswire
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board
PR Newswire
Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products
Globe NewsWire
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
Globe NewsWire
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of NGHC, GOCO, PSTX, and PROG; Shareholders are Encouraged to Contact the Firm
Globe NewsWire
POSEIDA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Poseida Therapeutics, Inc. on Behalf of Poseida Stockholders and Encourages Investors to Contact the Firm
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
Globe NewsWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Poseida Therapeutics, Inc. - PSTX
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Profile

Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.